Apr 17 |
Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share
|
Apr 17 |
Why Vanda Pharmaceuticals Stock Is Skyrocketing Today
|
Apr 17 |
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
|
Apr 17 |
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
|
Apr 17 |
Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer
|
Apr 15 |
Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors
|
Apr 10 |
Vanda Pharmaceuticals (VNDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
|
Apr 8 |
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
|
Apr 5 |
Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
|
Apr 4 |
Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?
|